



# IDEAYA Biosciences

Improving Lives  
Through Transformative  
Precision Medicines

NASDAQ: **IDYA**  
January 2024

## IDEAYA Highlights

**Breakthrough Science** on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

**Broad Pipeline** of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

**Proven Management Team** with deep business and scientific experience has built leading oncology companies

**Pharma Strategic Partnerships** with GlaxoSmithKline<sup>1</sup>, including ~\$2 billion in potential cash milestones, Pfizer<sup>2</sup> and Amgen<sup>3</sup>

**Strong Balance Sheet** of ~\$1.0 billion<sup>4</sup> with capital efficient model

**Analyst Coverage** by Capital One, Citi, Goldman Sachs, Jefferies, JP Morgan, Leerink, Oppenheimer, RBC, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements
- (3) Amgen Clinical Trial Collaboration and Supply Agreement
- (4) Includes aggregate of \$511.1M cash, cash equivalents and marketable securities as of September 30, 2023, plus pro forma \$134.7M estimated net proceeds from closing of underwritten public offering on October 27, 2023, \$10.0M receivable from GSK milestones, and \$342.7M estimated net proceeds from sales of common stock under the at-the-market offerings from January 4, 2024 to January 22, 2024